

RESEARCH

Open Access



A patient-derived mutation of epilepsy-linked *LG11* increases seizure susceptibility through regulating $K_v1.1$

Lin Zhou^{1†}, Kang Wang^{2†}, Yuxiang Xu^{3†}, Bin-Bin Dong¹, Deng-Chang Wu², Zhao-Xiang Wang¹, Xin-Tai Wang¹, Xin-Yu Cai¹, Jin-Tao Yang¹, Rui Zheng¹, Wei Chen^{1*}, Ying Shen^{1*}  and Jian-She Wei^{3*}

Abstract

Background Autosomal dominant lateral temporal epilepsy (ADLTE) is an inherited syndrome caused by mutations in the leucine-rich glioma inactivated 1 (LGI1) gene. It is known that functional LGI1 is secreted by excitatory neurons, GABAergic interneurons, and astrocytes, and regulates AMPA-type glutamate receptor-mediated synaptic transmission by binding ADAM22 and ADAM23. However, > 40 LGI1 mutations have been reported in familial ADLTE patients, more than half of which are secretion-defective. How these secretion-defective LGI1 mutations lead to epilepsy is unknown.

Results We identified a novel secretion-defective LGI1 mutation from a Chinese ADLTE family, LGI1-W183R. We specifically expressed mutant LGI1^{W183R} in excitatory neurons lacking natural LGI1, and found that this mutation down-regulated $K_v1.1$ activity, led to neuronal hyperexcitability and irregular spiking, and increased epilepsy susceptibility in mice. Further analysis revealed that restoring $K_v1.1$ in excitatory neurons rescued the defect of spiking capacity, improved epilepsy susceptibility, and prolonged the life-span of mice.

Conclusions These results describe a role of secretion-defective LGI1 in maintaining neuronal excitability and reveal a new mechanism in the pathology of LGI1 mutation-related epilepsy.

Keywords ADLTE, Epilepsy, Leucine-rich glioma inactivated 1, Precision medicine

Introduction

Epilepsy, characterized by recurrent seizures, is a common brain disorder that affects 1–2% of the population [1, 2]. At present, the therapeutic effect of antiepileptic drugs is not satisfactory. To develop novel therapeutic targets, it is essential to clarify the molecular mechanisms of seizure genesis. Autosomal dominant lateral temporal epilepsy (ADLTE) is an inherited syndrome caused by mutations in the leucine-rich glioma inactivated 1 (LGI1) gene, which encodes a secreted protein [3–12]. Haploinsufficiency of LGI1 has been suggested to be the major pathogenic basis for human ADLTE [4, 13, 14]. In mouse models, the global knockout of LGI1 results in generalized seizures and premature death [15–17], and the heterozygous knockout of LGI1 causes increased seizure

[†]Lin Zhou, Kang Wang and Yuxiang Xu contributed equally to this work

*Correspondence:

Wei Chen

srrcw@zju.edu.cn

Ying Shen

yshen@zju.edu.cn

Jian-She Wei

jswei@henu.edu.cn

¹ Department of Physiology and Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310020, China

² Department of Neurology, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China

³ School of Life Sciences, Henan University, Kaifeng 475004, China



susceptibility to either acoustic stimuli [15] or the convulsant agent pentylenetetrazole (PTZ) [16, 18].

It has been shown that functional LGI1 exists in excitatory neurons, interneurons, astrocytes, and oligodendrocytes [19, 20], and regulates the activity of K_v1 [18, 21–23] and AMPA-type glutamate receptor-mediated synaptic transmissions through binding to a disintegrin and metalloproteinases (ADAMs) [24, 25]. Furthermore, enhancing the interaction between the LGI1-ADAM22 complex and PSD-95 family proteins may prevent epilepsy [26–29], and restoring K_v1 activity using celecoxib, a drug approved by the Food and Drug Administration, ameliorates seizure susceptibility in global LGI1 knockout mice [18]. Although these strategies might be effective to reduce epileptic seizures in LGI1 knockout mice, clinical situation is much more complicated: >40 *LGII* mutations have been found in patients with familial ADLTE [3–12], highlighting the importance of the gene-mutation-cell-behavior relationship on an individual basis. However, how these LGI1 mutations lead to different disease phenotypes in ADLTE patients remains unclear. For example, 41 missense mutations of *LGII* yield either secretion-defective or -competent proteins [3–12, 26, 28], but the functions of the secretion-defective proteins, which cannot act on synaptic transmission as the extracellular binding partner of ADAM22/ADAM23, are almost unknown. It has been shown that LGI1 can act as a cytosolic protein to inhibit the inactivation of presynaptic K_v1 [21], and that LGI1 and K_v1 coexist in axonal initial segment [22]. Accordingly, we hypothesize that secretion-defective LGI1 proteins may act on K_v1 to regulate neuronal excitability.

Here, we identified a novel missense *LGII* mutation, p.Trp183Arg, from a Chinese ADLTE pedigree. To investigate the function of this mutant in the central nervous system (CNS), we used Cre-Loxp-based viral infection to specifically express mutant LGI1^{W183R} in mouse excitatory neurons that lacked native LGI1. Utilizing in vivo and in situ electrophysiological recordings and computer simulation, we found that the LGI1^{W183R} mutation produced secretion-defective LGI1 protein, which downregulated $K_v1.1$ activity, caused neuronal hyperexcitability and firing irregularity, and increased seizure susceptibility. Moreover, restoring $K_v1.1$ in excitatory neurons was able to correct the deficits in firing and ameliorate seizure susceptibility in mice.

Materials and methods

Clinical information

The proband, a 16-year-old man, came to the hospital due to repeated unconsciousness and generalized convulsions. The detailed clinical information of the proband and his family is shown in Additional files 11

and 12 (*Proband clinical information* and *Proband family sequencing result*). In brief, the form of his attacks was short-lived buzzing and tinnitus, followed by loss of consciousness, stiffness of the limbs, and foaming at the mouth, which lasted for ~2 min. He also suffered from isolated attacks of tinnitus, which occurred on average once a month. He was delivered naturally at full term, and the birth process was smooth, and his developmental milestones were normal. Physical examination of his nervous system was normal as well: MRI of his head showed no evident abnormality. However, video EEG monitoring showed occasional epileptiform discharges in the right temporal region. Initial treatment was valproic acid (0.5 g) twice a day, but he still had seizures. Then oxcarbazepine (0.3 g) was added twice a day, and the proband remained free of attacks for 4 years. The proband's father had similar seizures at the age of 18, took carbamazepine (0.2 g) twice a day, and had no attacks for ~20 years. The proband's grandfather had a grand mal seizure at the age of 19 and often auditory aura since that time, but did not take antiepileptic drugs, thereby living with seizures every 3–5 years.

Patient EEG recording

A 20-h EEG dataset was collected using a Nicolet V32 EEG monitor (Natus Neurology Inc.) with 21 electrodes according to the international 10–20 system. During recording, the Fz electrode served as the common reference. EEG signals were sampled at 256 Hz and band-pass-filtered at 0.01–100 Hz. To guarantee data quality, the impedance of all electrodes was calibrated at <5 K Ω before acquisition. During EEG recording, one camera was used to monitor the behavior of the patient. The data were read and analyzed by two epileptologists independently.

Animals

LGII^{fllox/fllox} mice (Loxp-flanked encompassing exons 5 and 7) were created at the Model Animal Research Center of Nanjing University. All mice were maintained at the Experimental Animal Center of Zhejiang University and kept in temperature-controlled conditions under a 12:12 h light/dark cycle with food and water ad libitum. Male mice were used in all experiments.

Antibodies and reagents

Following antibodies and reagents were used: anti-NeuN (#MAB377) and anti-GAPDH (#MAB374) from Millipore, DTx-K (#ab141795) and anti-LGI1 (#ab30866) from Abcam, anti-CaMKII α (#611292) from Bio-rad, anti-Iba1 (#SAG4318) from Wako, anti-GFAP (#Z0334) from DAKO, anti-PV (#235) from SWAT, anti-Flag (#T20008) from Abmart, and Goat anti-mouse/rabbit IgG

horseradish peroxidase-conjugated antibodies (#31446 and #31460) from Thermo Fisher Scientific. Other reagents were from Sigma or Tocris unless stated otherwise.

Cell culture and DNA transfection

HEK293 cells were cultured in DMEM and supplemented with 10% FBS in an incubator (95% O₂/5% CO₂; 37 °C). Cells were transfected in OPTI-MEM with plasmids using lipofectamine 2000. Cells were treated with CHX (50 μM) to inhibit protein synthesis at 24, 32, 40 and 44 h after the transfection [30]. Cells were harvested 48 h after the transfection and lysed in RIPA buffer (1% Triton X-100, 0.5% deoxycholate, 0.2% SDS, 100 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl; pH 7.4) plus protease inhibitors and centrifuged at 10,000 × *g* at 4 °C for 20 min to collect supernatant fractions.

For Co-IP experiments, HEK293 cells were harvested 48 h after transfection with Flag-LGI1^{WT} or Flag-LGI1^{W183R}, lysed in RIPA buffer plus the protease inhibitor and centrifuged at 10,000 × *g* at 4 °C for 20 min to collect supernatant fractions. These fractions were incubated with rabbit anti-Flag antibody, which was pre-coupled to protein A-sepharose beads for 2 h at 4 °C. Proteins on the beads were washed 3 times with 50 mM Tris-HCl and extracted with 2 × SDS sample buffer. Protein samples were immunoblotted with mouse ubiquitin antibody.

Western blotting

Samples were rinsed with PBS and diluted in a 1% SDS-containing protease inhibitor mixture. After determining the protein concentration using BCA protein assay, equal quantities of protein were loaded and fractionated on SDS-PAGE gels, transferred to PVDF membranes, immunoblotted with antibodies, and visualized by enhanced chemiluminescence. The primary antibody dilutions were 1:1000 for LGI1 and 1:10,000 for GAPDH. The secondary antibodies were anti-rabbit (1:10,000) and anti-mouse (1:10,000). Film signals were digitally scanned and protein levels were quantified by measuring the integrated optical densities of the bands after background subtraction using ImageJ 1.42q (NIH).

RNA preparation and real-time PCR

mRNA levels were assessed by real-time PCR using an ABI PRISM 7500 sequence detection system (Applied Biosystems). cDNA was synthesized by reverse transcription using oligo (dT) as the primer and proceeded to real-time PCR with gene-specific primers in the presence of SYBR Premix Ex Taq. Quantification was performed by the comparative cycle threshold (Ct) method, using GAPDH as the internal control. Following forward (F) and reverse (R) primers were used to amplify: *LGI1*-F:

5'-GCT GCA GCT CTT GTT ATT TAC GTC G-3', and *LGI1*-R: 5'-GAG CCA TTC CAC CAG CCA CTT CAA C-3'. *GAPDH*-F: 5'-TGT TAC CAA CTG GGA CGA CA-3', and *GAPDH*-R: 5'-AAG GAA GGC TGG AAA AGA GC-3'.

Immunohistochemistry

Coronal cortical sections were cut at 25 μm and placed in a blocking solution (1% BSA, 0.3% triton, 10% normal goat serum) for 1 h at RT. After washing with PBS, the sections were incubated with primary antibodies overnight at 4 °C and then incubated with secondary antibody for 1 h at RT. These sections were then mounted using ProLong Gold Antifade reagent with DAPI. The antibody dilutions were 1:250 (CaMKIIα), 1:500 (Iba1 and GFAP), 1:1000 (NeuN, Alexa Fluor 594/647-conjugated goat anti-rabbit IgG, and 594/647-conjugated goat anti-mouse IgG), and 1:2000 (PV). All antibodies were diluted in PBS containing 1% BSA and 1% normal goat serum.

Intracranial injection

P0 pups were cryoanesthetized at − 20 °C for 2–3 min before injection. A solution of AAV containing 0.05% trypan blue was injected bilaterally into the ventricles using a 10-μl syringe with a 32-gauge needle (Hamilton). The injection site was located 2/5 of the distance along a line defined between each eye and the lambda intersection of the skull at a depth of 3 mm. Viral solution (2 l) was injected into each lateral ventricle (AAV final unit at 1 × 10¹³ viral genomes/ml). After injections, pups were placed on a warming pad, and then returned to their mothers for care [31].

PTZ-induced seizures

Seizures were measured in mice (P35) injected with PTZ at 45 mg/kg (i.p.). The seizure activity was observed and scored by investigators who were blinded to the genotype throughout the experiments. Seizures were scored for 30 min after the injection as follows [18]: 1, hypoactivity (abdomen in full contact with the bottom of the cage in the resting position); 2, focal clonus (of face, head, or forelimbs); 3, generalized clonus (rearing, falling, and clonus of four limbs and tail); and 4, clonic (tonic seizure, tonic hindlimb extension, or death).

Mouse EEG recording

Mice were deeply anesthetized with pentobarbital (30 mg/kg) and placed in a stereotaxic apparatus (Stoelting). Recording electrodes (#795500, A. M. Systems) made of twisted stainless-steel wires (diameter: 0.125 mm) insulated with Teflon were implanted into the hippocampal CA1 region (in mm; bregma: − 2.0; mediolateral: ± 2.0; dorsoventral: − 1.5) according to the

Paxinos and Franklin mouse brain atlas [32]. Two screws were placed in the skull over the cerebellum to serve as the reference and ground electrodes. The maximal tip separation between recording and reference electrodes was 0.5 mm. After complete recovery from the surgery, the mice were placed in a transparent cage and allowed to move freely. EEG signals were band-pass filtered spanning DC to 200 Hz and sampled at 2 kHz using an amplifier (Neuroscan System). EEG recordings were continued for 30 min after PTZ injection [18, 33].

In vitro electrophysiology

Coronal slices of the hippocampus (300 μm) from P17–20 mice were cut in ice-cold aCSF (in mM: 125 NaCl, 3 KCl, 1.25 NaH_2PO_4 , 2 MgSO_4 , 2 CaCl_2 , 25 NaHCO_3 , 10 glucose) on a vibrating tissue slicer (VT 1000S, Leica). After recovery for 30 min at 37 $^\circ\text{C}$, the slices were incubated at room temperature (RT) for 60 min and then transferred to the recording chamber and superfused at 2 ml/min with aCSF at RT. All solutions were saturated with 95% O_2 /5% CO_2 .

Neurons were visualized under an upright microscope (BX51, Olympus) with a 40 \times water-immersion objective equipped with infrared differential interference contrast enhancement. Whole-cell recordings were made with an Axon MultiClamp 700B amplifier (Molecular Devices). Glass pipettes (3–5 $\text{M}\Omega$) were filled with a solution containing (in mM): 120 K-gluconate, 20 KCl, 10 HEPES, 2 MgCl_2 , 10 Na-phosphocreatine, 4 Mg-ATP, 0.3 Na-GTP, 0.1 EGTA (pH 7.3; 290 Osm). Currents were filtered at 2 kHz and digitized at 10 kHz. Recordings were excluded from analysis if series resistance, input resistance, or holding current varied by 15% over the course of an experiment. All electrophysiological experiments were performed at RT.

Passive neuronal properties were measured from single APs. The rheobase was defined as the minimum depolarizing current needed to elicit an AP. AP amplitude was measured as the voltage difference between peak and resting potentials. The half-width was determined at half of spike amplitude. The input–output relationship between injected currents and spikes was determined when neurons received a series of currents ranging from 20 to 200 pA (20-pA increments) with a duration of 800 ms. The fast AHP was defined as the slope of the 3-ms V_m immediately following the spike [34, 35]. For mEPSC recording, the neurons were held at -70 mV in the presence of TTX (1 μM) and GABAzine (20 μM). To measure K^+ currents, TTX (1 μM) and CdCl_2 (100 μM) were added to the aCSF to block Na^+ and Ca^{2+} channels, and a series of voltage pulses (3 s) from -70 mV to 40 mV (10-mV increment) were applied under the voltage-clamp configuration. $\text{K}_v1.1$ activation/inactivation

curves were constructed from steady-state currents after the conversion to conductance, normalized to the maximum conductance, and fitted with a single Boltzmann equation [18, 36].

Non-stationary noise analysis

In order to estimate single-channel current (I) and available number of channels (N), peak-scaled non-stationary noise analysis was applied to each ensemble of $\text{K}_v1.1$ current simulated with an activation command pulse, based on previous work [37–40]. The peak of mean current response waveform was scaled to the response value at the corresponding point in time of each individual event [41]. In this case, N corresponded to the average number of channels open at the peak. To assign similar weights to all phases of the ensemble mean waveform, from the peak to the end of the decay, the amplitude interval from the peak to the baseline was divided into an equal number of intervals [41, 42]. The amplitude intervals were then translated to the corresponding time intervals, and the variance and mean current were calculated for each interval over all the event waveforms using Excel software (Microsoft). Leak was subtracted off-line with subtraction pulses collected throughout the run. The variance was plotted against the mean current and the data points were fitted with a parabolic function [37], omitting the rising phase of the response: $\sigma^2(I) = iI - I^2/N$, where for any given potential, σ^2 was the variance, i was the single channel current, I was the macroscopic mean current, and N was the number of channels. The values for N and i were then estimated from the fit of the variance vs mean data to the equation.

Computer simulation

The simulation was carried out using NEURON v7.5 software. In the three-dimensional computational model of a CA1 pyramidal neuron [43, 44], uniform passive parameters ($\tau_m = 28$ ms; $C_m = 0.75$ $\mu\text{F}/\text{cm}^2$; $R_m = 37.3$ $\text{K}\Omega/\text{cm}^2$) were set for the entire neuron and RMP was set at -65 mV. The kinetics and distribution of active somatic, dendritic and axonal channels, including I_{Na} , I_{DR} (delayed rectifier K^+), I_{A} (transient K^+), I_{KM} (M K^+), $\text{K}_v1.1$, and I_{h} (non-selective hyperpolarization-activated channels), were defined according to data available for CA1 pyramidal neurons [45]. The conductance of low-threshold Ca^{2+} and Ca^{2+} -dependent K^+ and Ca^{2+} extrusion machinery was also included in the neuronal model. The densities of I_{Na} and I_{DR} were set to 450 and 200 $\text{pS}/\mu\text{m}^2$, respectively, at the soma and apical dendrites, and their density in axons was increased threefold. The somatic density of I_{A} and I_{h} were 300 and 0.1 $\text{pS}/\mu\text{m}^2$, respectively, and they were increased linearly with distance from the soma. I_{KM} was inserted into the soma at a density of 60 $\text{pS}/\mu\text{m}^2$ and

into the axon at a fourfold higher density. The conductance of Ca^{2+} and Ca^{2+} -dependent K^{+} channels was set to 1 and 0.1 $\text{pS}/\mu\text{m}^2$, respectively. $\text{K}_v1.1$ was set at a uniform density of 100 $\text{pS}/\mu\text{m}^2$ in both the soma and the axon [46]. The steady-state activation curve and time constants for $\text{K}_v1.1$ ($V_{1/2} = -30$ mV) were defined according to previous work [47].

Statistical analysis

Data were analyzed using GraphPad Prism 8.0 (GraphPad Software) and Igor Pro 6.0 (Wavemetrics). Statistical differences were determined using the unpaired *t* test with Welch's correction for two-group comparisons or 2-way ANOVA followed by Bonferroni's post hoc test for multiple comparisons. Survival curves were analyzed by Kaplan–Meier survival estimate using the log-rank test. The accepted level of significance was $P < 0.05$. *n* represents the number of animals or cells. Data in the text and figures are presented as the mean \pm SEM.

Results

A novel missense LGI1 mutation produces a secretion-defective LGI1 protein

We treated a 16-year-old Chinese man who developed recurrent epileptic seizures (see Materials and Methods and Additional file). His episodes were characterized by generalized tonic–clonic seizures preceded by auditory auras. His father and grandfather had similar manifestations from the puberty, strongly indicating ADLTE [5, 48]. We applied whole-exome sequencing using a blood sample of the proband, and identified a novel missense LGI1 variant, c.547 T (p.Trp183Arg) (Fig. 1A, B), which is absent from the ExAC, dbSNP, 1000G, and gnomAD databases. Moreover, both his father and grandfather carried the same heterozygotic variant (Fig. 1A), consistent with a pattern of autosomal dominant inheritance. The Trp183 residue is highly conserved throughout vertebrate species (Fig. 1C), and is located in the C-cap domain of LGI1 (Fig. 1C, D). The brain magnetic resonance imaging (MRI) of the proband appeared normal (Fig. 1E). The drug treatment we provided effectively controlled his seizures (see Additional file), and thereby only brief and occasional interictal epileptiform discharges were detected after the treatment (Fig. 1F).

To characterize this missense mutation, we generated plasmids encoding wild-type LGI1 (LGI1^{WT}) or mutant $\text{LGI1}^{\text{W183R}}$, and transfected them into HEK cells. mRNA analysis revealed no difference in the level of transcripts between $\text{LGI1}^{\text{W183R}}$ and LGI1^{WT} (Fig. 1G). Western blots with anti-LGI1 antibody also showed no difference in the protein level between $\text{LGI1}^{\text{W183R}}$ and LGI1^{WT} (Fig. 1H). It has been shown that some of *LGI1* mutations yield secretion-defective LGI1 proteins [26, 28]. To investigate

whether $\text{LGI1}^{\text{W183R}}$ mutation leads to defective secretion, we measured LGI1 protein in conditioned medium and cell lysates, and found that LGI1^{WT} protein was secreted by HEK cells, whereas $\text{LGI1}^{\text{W183R}}$ protein was not (Fig. 1I). We compared the stability of LGI1^{WT} and $\text{LGI1}^{\text{W183R}}$ proteins in the cell lysates using cycloheximide (CHX) treatment. The expressions of both LGI1^{WT} and $\text{LGI1}^{\text{W183R}}$ proteins were reduced over time during CHX treatment, but the rate of decrease of LGI1^{WT} was much faster than that of $\text{LGI1}^{\text{W183R}}$ (Fig. 1J), which might be due to the secretion of LGI1^{WT} . To investigate whether the $\text{LGI1}^{\text{W183R}}$ mutation affects LGI1 ubiquitination, we added ubiquitin to HEK cells and found that both LGI1^{WT} and $\text{LGI1}^{\text{W183R}}$ proteins were ubiquitinated to the same extent, implying that $\text{LGI1}^{\text{W183R}}$ mutation does not affect the degradation of LGI1 (Fig. 1K).

Expressing $\text{LGI1}^{\text{W183R}}$ in excitatory neurons results in epileptic seizures

Previous work has shown that the depletion of LGI1 in excitatory neurons is critical to the onset of seizures [19], highlighting the importance of excitatory neurons in ADLTE. Hence, we hypothesized that the pathogenic mechanism of $\text{LGI1}^{\text{W183R}}$ mutation is dependent of excitatory neurons. To test this idea, we expressed $\text{LGI1}^{\text{W183R}}$ solely in excitatory neurons in the brain. First, we applied Cre-Loxp technique to generate *LGI1*^{fllox/+} mice (Fig. 2A), which were further intercrossed with CaMKII-Cre mice to obtain either CaMKII-Cre;*LGI1*^{fllox/+} (Het) or CaMKII-Cre;*LGI1*^{fllox/fllox} (cKO), where LGI1 was either haploinsufficient or deficient in excitatory neurons (Fig. 2B). Next, we injected AAV9-DIO-LGI1^{WT}-GFP or AAV9-DIO-LGI1^{W183R}-GFP bilaterally into the ventricles of either Het or cKO mice at P0 (Fig. 2B). With this approach, LGI1^{WT} -GFP or $\text{LGI1}^{\text{W183R}}$ -GFP was specifically expressed in excitatory neurons, in which endogenous LGI1 was deleted or haploinsufficient. Finally, cKO or Het mice with exogenous LGI1^{WT} or $\text{LGI1}^{\text{W183R}}$ were subjected to video monitoring of autonomous or PTZ-induced epileptic seizures and/or electroencephalogram (EEG) recordings (Fig. 2B). With this strategy, the expression of LGI1^{WT} or $\text{LGI1}^{\text{W183R}}$ was confirmed by confocal imaging of GFP fluorescence and CaMKII α expression. We found that the GFP signal was broadly expressed in the cerebral cortex and the hippocampus (Fig. 2C). Moreover, GFP signal was well co-localized with CaMKII α signal (Fig. 2C), indicating the specific expression of LGI1^{WT} and $\text{LGI1}^{\text{W183R}}$ proteins in excitatory neurons. Counting the numbers of neurons showed no difference in the ratio of GFP-positive neurons among CaMKII α -positive neurons between the LGI1^{WT} and $\text{LGI1}^{\text{W183R}}$ groups at two developmental stages, P17–20 and P35 (Fig. 2D). These results indicate that, with our strategy, exogenous




Fig. 1 Genetic and expression analysis of the *LGI1*^{W183R} mutation. **A** Pedigree of the *LGI1*^{W183R} variant. (square, male; circles, females; see Additional file for details). **B** Chromatograms of c.547T>C within *LGI1*. (upper, normal sequence; lower, mutant sequence). **C** Upper, domains within the *LGI1* protein: N-cap, LRR, C-cap, and EPTP. The *LGI1*^{W183R} mutation maps onto the C-cap domain. Lower, alignment analysis of *LGI1* orthologues in different vertebrate species shows the conservation of the W183 residue. **D** Mapping of the *LGI1*^{W183R} mutation on the 3D structure of *LGI1*. **E** Brain MRIs of the proband showing normal brain structure (horizontal, coronal, and sagittal views from left to right). **F** Representative EEG recording from the proband (arrowhead), an epileptiform discharge during the interictal period; left electrodes from the Bipolar Montage. **G** mRNA levels of *LGI1* in HEK cells transfected with *LGI1*^{WT} or *LGI1*^{W183R}. **H** Total *LGI1* protein in cultures transfected with *LGI1*^{WT} or *LGI1*^{W183R}. **I** *LGI1* expression in the medium (secreted) and cell lysates of cultures transfected with *LGI1*^{WT} or *LGI1*^{W183R}. **J** *LGI1* protein levels at annotated time points in HEK cells transfected by *LGI1*^{WT} or *LGI1*^{W183R} and continuously treated with CHX. **K** Immunoprecipitation with rabbit anti-Flag antibody followed by western blots using mouse anti-Flag antibody and mouse anti-Flag-ubiquitin show no difference in *LGI1* ubiquitination level between the two groups (Flag-*LGI1*^{WT} or Flag-*LGI1*^{W183R} transfected into HEK cells). See Additional file 4: Table S1 for statistics. **P < 0.01. ***P < 0.001

LGI1^{WT} and *LGI1*^{W183R} proteins are robustly expressed in excitatory neurons upon the viral injection of *LGI1*^{WT} or *LGI1*^{W183R} into the ventricles. This conclusion was further strengthened by confocal imaging of GFP and the specific marker proteins for other major types of brain cells, including parvalbumin (PV)-positive interneurons, astroglia, and microglia (Additional file 1: Fig. S1).

The loss of *LGI1* in excitatory neurons causes epileptic seizures and premature death [19]. Accordingly, we considered whether *LGI1*^{W183R} protein in excitatory neurons may lead to these phenotypes as well. The majority of cKO::*LGI1*^{W183R} mice (17/19) died before P21 and their median lifetime was 22 days, as shown

in the Kaplan–Meier survival curves (Fig. 2E). In contrast, cKO::*LGI1*^{WT}, Het::*LGI1*^{WT} and Het::*LGI1*^{W183R} littermates survived for >40 days (Fig. 2E). The cKO::*LGI1*^{W183R} mice often had spontaneous seizures (generalized tonic or clonic seizures) (Additional file 9: Video S1) at an onset age of P16 with a frequency between 0.25 and 1 per hour and a mean duration of 45.5 ± 18.7 s (Additional file 6: Table S2). In contrast, cKO::*LGI1*^{WT}, Het::*LGI1*^{WT} and Het::*LGI1*^{W183R} mice displayed no autonomous seizures. Because mutant mice with *LGI1* haploinsufficiency display increased seizure susceptibility to PTZ [28], we examined PTZ-induced seizures in Het::*LGI1*^{WT} and Het::*LGI1*^{W183R}




Fig. 2 Expressing LGI1^{W183R} in excitatory neurons increases seizure susceptibility. **A** Gene targeting strategy for the generation of LGI1^{loxP/loxP} mice. **B** AAV9-DIO-LGI1^{WT}-GFP or AAV9-DIO-LGI1^{W183R}-GFP is expressed in cKO or Het excitatory neurons (CaMKII-Cre). Viruses are bilaterally injected into the ventricles (P0). cKO mice subjected to video observation and electrophysiological recording at P17–20 and Het mice are subjected to PTZ treatment and EEG recording at P35. **C** Representative images for triple fluorescence, GFP, CaMKII(CKII) and DAPI, in the hippocampus (hip) and temporal cortex (temp lb) of cKO mice (P17) (scale bars: 1 mm (whole brain); 50 μm (magnified)). **D** Number ratios of GFP + vs CaMKII + cells in cKO and Het mice expressing LGI1^{WT} or LGI1^{W183R} (n = 5 per group). At P17–20, the ratio of GFP + vs CaMKII + is 43 ± 4 (CA1; LGI1^{WT}) and 42 ± 4 (CA1; LGI1^{W183R}), P = 0.86; 41 ± 4 (temp lb; LGI1^{WT}) and 42 ± 5 (temp lb; LGI1^{W183R}), P = 0.86. At P35, the ratio of GFP + vs CaMKII + is 44 ± 5 (CA1; LGI1^{WT}) and 44 ± 5 (CA1; LGI1^{W183R}), P = 0.98; 42 ± 3 (temp lb; LGI1^{WT}) and 38 ± 5 (temp lb; LGI1^{W183R}), P = 0.47. **E** Kaplan–Meier survival curves. **F** Quantification of reactions to PTZ injection. Latency to generalized seizure (GS): 383 ± 50 s (Het::LGI1^{WT}; n = 5) and 212 ± 33 s (Het::LGI1^{W183R}; n = 10), P = 0.023. **G** Representative EEGs and power spectral analysis in Het::LGI1^{WT} and Het::LGI1^{W183R} mice (P35) during PTZ-induced seizures. **G'** Enlarged view of EEGs in **G**. **H** Spectral analysis of the EEGs. Grey dots indicate individual data points. *P < 0.05

mice at P35. Our results showed that, compared to Het::LGI1^{WT} mice, seizure severity was significantly greater in Het::LGI1^{W183R} mice, as shown by more frequent generalized seizures: the majority of Het::LGI1^{W183R} mice (10/15) were at stages 3/4 and displayed a shortened latency to generalized seizures, whereas the majority of Het::LGI1^{WT} (10/15) mice were at stages 1/2 (Fig. 2F). The behavioral difference was

confirmed by EEG recordings. Energy spectra of representative epileptic EEGs recorded from Het::LGI1^{WT} and Het::LGI1^{W183R} mice are shown in Fig. 2G and the absolute power at each firing frequency is shown in Fig. 2H. These results indicated that expressing LGI1^{W183R} in excitatory neurons augmented PTZ-induced seizure severity compared to expressing LGI1^{WT} (Fig. 2G, H). Taken together, we conclude that

LGII^{W183R} in excitatory neurons is sufficient to cause epileptic seizures in mice.

LGII^{W183R} causes hyperexcitability and firing irregularity in hippocampal pyramidal neurons

To investigate the mechanism by which LGII^{W183R} regulate neuronal activity, we performed whole-cell recordings in hippocampal CA1 pyramidal neurons of cKO::LGII^{WT} and cKO::LGII^{W183R} mice aged P17–20 (Fig. 3A). Single action potentials (APs) were induced by rheobase current injection and their major kinetic parameters were analyzed (Fig. 3B). We found that cKO::LGII^{W183R} neurons required a smaller rheobase

than cKO::LGII^{WT} neurons, but showed no difference in membrane capacitance between two groups (Fig. 3C). The plots of rate of change membrane potential (dV/dt) vs membrane potential revealed that AP waveform differed between cKO::LGII^{WT} and cKO::LGII^{W183R} neurons (Fig. 3D). In cKO::LGII^{W183R} neurons, AP threshold was more hyperpolarized, the half-width was increased, and the values of dV/dt at +20 mV and -40 mV were increased (Fig. 3E). Meanwhile, AP amplitude and resting membrane potential (RMP) were unaltered (Fig. 3E). The altered AP parameters indicated that exogenous LGII^{W183R} may influence the generation of AP. In fact, rheobase




Fig.3 Hyperexcitability and spiking irregularity in hippocampal neurons expressing LGII^{W183R}. **A** Schematic of whole-cell recording in cKO CA1 pyramidal neurons expressing LGII^{WT}-GFP or LGII^{W183R}-GFP (pip: patch pipette). **B** AP evoked by a rheobase current (black), but not subthreshold currents (grey) (arrows, threshold, RMP, amplitude, and half-width. **C** Averages of membrane capacitance (Cm) and rheobase. **D** Left: example APs in cKO::LGII^{WT} and cKO::LGII^{W183R} neurons. Right: phase-plane plots for APs. The arrowheads show the measurement of threshold and dV/dt at 0, +20 (repolarization) and -40 mV. **E** Averages of RMP, threshold, half-width, amplitude, dV/dt at 0 mV, dV/dt at +20 mV, and dV/dt at -40 mV. **F** Left: example APs induced by rheobase current in cKO::LGII^{WT} and cKO::LGII^{W183R} neurons. Right: probabilities of doublet APs. **G** Left: example spikes recorded in cKO::LGII^{WT} and cKO::LGII^{W183R} neurons responding to 80-pA and 200-pA currents. Right: numbers of spikes as a function of injected currents. **H** Left: representative 1st and last spikes induced by 200-pA current. Middle: half-widths of 1st spikes induced by different currents plotted against to currents. Right: ratios of last vs 1st spikes were plotted against corresponding currents. **I** Left: example firing showing spike-timing reliability. Right: plots of intraburst jitters as a function of recording time. **J** Averages of 1st ISI frequency, CV, and CV₂. **K** Left: example AHPs. Right: plots of fast AHP as a function of spikes. Insets amplification of 2nd and 4th AHPs. See Additional file 8: Table S3 for statistics. Grey dots indicate individual data points. *P<0.05. **P<0.01. ***P<0.001

current that induced a single AP in cKO::LGI1^{WT} neurons could evoke doublet APs in cKO::LGI1^{W183R} neurons (Fig. 3F), suggesting that cKO::LGI1^{W183R} neurons are more excitable than cKO::LGI1^{WT} neurons.

Next, the population firings in pyramidal neurons were induced by a depolarizing step current. We found that an 80-pA current produced more spikes in cKO::LGI1^{W183R} neurons than in cKO::LGI1^{WT} neurons (Fig. 3G), suggesting that LGI1^{W183R} increases the firing potential. Unexpectedly, further study demonstrated that a 200-pA current produced fewer spikes in cKO::LGI1^{W183R} neurons, which was manifested by the input–output curves (injected current–number of spikes) obtained from cKO::LGI1^{WT} and cKO::LGI1^{W183R} neurons (Fig. 3G). Previous work has suggested that altered AP half-width is the reason for such bi-directional changes accompanying increasing stimulation intensities [36]. Indeed, we showed that AP half-width was increased by LGI1^{W183R} (Fig. 3E). To test if this is the case for population firing, we measured the half-width of the 1st spike evoked by increasing stimuli (80–200 pA), and found that the values were always larger in cKO::LGI1^{W183R} neurons than in cKO::LGI1^{WT} neurons (Fig. 3H). Furthermore, we calculated the ratio of half-width of the last vs the 1st spikes. Our results demonstrated that: the spike became wider in both cKO::LGI1^{WT} and cKO::LGI1^{W183R} neurons as time passed; but this ratio was always greater in cKO::LGI1^{W183R} neurons than in cKO::LGI1^{WT} neurons (Fig. 3H), which explained the reduced number of spikes upon stimulation with large currents.

Also, we noted that the 1st interspike interval (ISI) in a firing was shorter in cKO::LGI1^{W183R} neurons (Fig. 3G). To clarify this point, we adjusted the intensity of injection currents (60–80 pA) to induce exactly 7 spikes in recorded neurons (Fig. 3I) [49], and measured two parameters: 1st ISI frequency, which was augmented significantly in cKO::LGI1^{W183R} neurons (Fig. 3J), and the regularity of firing, which was characterized by the coefficient of variation of all ISIs (CV) and the coefficient of two consecutive ISIs (CV₂) [50]. As shown by event rasters (Fig. 3I) and statistics of CV and CV₂ (Fig. 3J), the firing became more irregular in cKO::LGI1^{W183R} neurons than in cKO::LGI1^{WT} neurons. It has been suggested that the ISI depends on the after-hyperpolarization potential (AHP) [34, 35], which can be separated into two parts, fast and slow AHPs [51, 52]. In our hands, we found that the fast AHP was decreased for the second and third spikes in cKO::LGI1^{W183R} neurons, but the difference gradually declined over time (Fig. 3K). Thus, these altered fast AHP may explain the irregularity of spontaneous spikes in cKO::LGI1^{W183R} neurons.

K_v1.1 activity is down-regulated in cKO::LGI1^{W183R} neurons

A putative function of LGI1 is its modulation of glutamatergic transmission through binding ADAMs [24, 25]. However, the LGI1^{W183R} mutation unlikely plays this role, since it yields a secretion-defective LGI1 protein. Indeed, we found that neither the amplitude nor the frequency of mEPSCs was altered by LGI1^{W183R} expression in cKO neurons (Additional file 2: Fig. S2). Alternatively, LGI1^{W183R} may act on ion channels, as we had previously demonstrated that K_v1 is down-regulated in cortical neurons upon LGI1 ablation [18]. To test this possibility, we made whole-cell recordings in cKO hippocampal neurons expressing LGI1^{WT}-GFP or LGI1^{W183R}-GFP with perfusion of DTx-K (a specific K_v1.1 antagonist [53, 54]) (Fig. 4A). By applying a series of stepped voltage pulses to neurons, we obtained K_v1.1 current by subtracting DTx-K-sensitive current from overall K⁺ current (Fig. 4B). Our results showed an overall decrease in K_v1.1 current in cKO::LGI1^{W183R} neurons (Fig. 4B), indicating that LGI1^{W183R} inhibits K_v1.1 current. This conclusion was strengthened by analyzing the activation and inactivation of K_v1.1 current, which were defined as the currents evoked by depolarizing voltages and the currents evoked by 3-s inactivating pre-pulses, respectively [18]. As shown by normalized conductance recorded at stepped voltages (from –70 to +40 mV), both the activation and the inactivation of K_v1.1 current were reduced by LGI1^{W183R} expression (Fig. 4C, D). Further kinetics analysis showed no effect of LGI1^{W183R} on the slope of activation curve and half-activation voltage, and that there was an increase in half-inactivation voltage, but not the slope of the inactivation curve, following LGI1^{W183R} expression (Fig. 4E). These analyses reveal that LGI1^{W183R} exerts strong regulatory effects on K_v1.1 activity, which can alter the waveform of the AP and spiking pattern [36, 55–58]. To determine the cause of K_v1.1 current reduction, i.e. whether it is due to a reduction of single-channel conductance or the number of active channels, we performed non-stationary noise analysis on the activation of K_v1.1 in cKO neurons expressing LGI1^{WT} or LGI1^{W183R} at a command voltage of +40 mV [59, 60]. Plotting current variance as a function of current amplitude yielded a parabola, whose parameters are suitable to determine single-channel conductance and the number of active channels [59, 60]. Our analysis indicated that LGI1^{W183R} expression reduced the number of active K_v1.1 channel (8417 for LGI1^{WT} and 5936 for LGI1^{W183R}), while single-channel conductance was not affected (0.31 for LGI1^{WT} and 0.33 for LGI1^{W183R}) (Fig. 4F). These data show that the reduction in K_v1.1 current is due to a reduced number of active channels.

If LGI1^{W183R} reduces K_v1.1 activity, it is reasonable to assume that inhibiting K_v1.1 is able to annihilate the




Fig. 4 Downregulation of $K_v1.1$ activity in $cKO::LG1^{W183R}$ neurons. **A** Schematic of whole-cell recording in $cKO::LG1^{WT}$ and $cKO::LG1^{W183R}$ neurons perfused with DTx-K. **B** Activated K^+ current by stepped voltage pulses (-70 to $+40$ mV) in neurons before and after application of DTx-K (100 nM). $K_v1.1$ current (DTx-K-sensitive) are from current subtraction. **C** $K_v1.1$ current during the activation phase normalized to cell capacitance (current density) and plotted against command voltage. **D** The inactivation of $K_v1.1$ current by stepped voltage pulses (-70 to $+10$ mV). **E** Left, steady-state activation and inactivation curves of $K_v1.1$ current normalized to maximal conductance. Right, averages of half-voltages for the activation and inactivation curves. **F** Non-stationary noise analysis of $K_v1.1$ activation at a command voltage of $+40$ mV. Current variance is plotted against the amplitude at a given time point. Single-channel conductance and number of active channels are determined by fitting a parabola to the data points. **G** Example APs induced by rheobase in $LG1^{WT}$ and $LG1^{W183R}$ neurons treated with DTx-K. **H** Averages of AP threshold, rheobase, half-width, and amplitude with the addition of DTx-K. **I** Curves of spikes vs injected current in neurons perfused with DTx-K. **J** Left: averages of half-width of 1st spike induced by different current injections in neurons perfused with DTx-K. Right: ratios of last vs 1st spikes plotted against injected current. **K** Plots of intraburst jitters as a function of recording time in neurons perfused with DTx-K. **L** Average values of 1st ISI frequency, CV, and CV_2 in neurons perfused with DTx-K. See Additional file 5: Tables S4 for statistics. Grey dots indicate individual data points. * $P < 0.05$. ** $P < 0.01$. *** $P < 0.001$

difference in intrinsic excitability between $cKO::LG1^{WT}$ and $cKO::LG1^{W183R}$ neurons. To test this idea, we perfused DTx-K onto cKO neurons expressing either $LG1^{WT}$ or $LG1^{W183R}$, and examined the AP and spikes. Under this condition, AP waveform showed similar kinetics in $cKO::LG1^{WT}$ and $cKO::LG1^{W183R}$ neurons (Fig. 4G). The statistics showed no difference between $cKO::LG1^{WT}$ and $cKO::LG1^{W183R}$ neurons in a number of AP parameters, including threshold, rheobase, half-width, and peak amplitude (Fig. 4H). Again with stepped current injection, we compared the number of

spikes, half-width of 1st spike, half-width ratio of the last vs 1st spike, and spiking regularity, which were shown to differ between $cKO::LG1^{WT}$ and $cKO::LG1^{W183R}$ neurons (Fig. 3). With the perfusion of DTx-K, no difference was found in the numbers of spikes for all intensities of injected currents, as shown by the input-output curves (Fig. 4I). We induced 7 spikes in $cKO::LG1^{WT}$ and $cKO::LG1^{W183R}$ neurons with the perfusion of DTx-K. Likewise, DTx-K eliminated the differences in the half-width of 1st spike and half-width ratio of the last vs 1st spike, when $cKO::LG1^{WT}$ and $cKO::LG1^{W183R}$

neurons were injected with the same current (Fig. 4J). In addition, DTx-K application changed the firing of cKO::LGII^{WT} neurons, making the pattern equal to that of cKO::LGII^{W183R} neurons (Fig. 4K). The statistics showed that the values of 1st ISI frequency, CV, and CV₂ were all increased by DTx-K application in cKO::LGII^{WT} neurons, while these parameters were not altered in cKO::LGII^{W183R} neurons (Fig. 4L), thereby eliminating the differences between two groups. Taken together, we conclude that a reduction in K_v1.1 activity is the cause of the abnormal excitability in cKO neurons expressing LGII^{W183R}.

K_v1.1 control spiking pattern of pyramidal neurons: evidence from computer simulation

To better elucidate the contribution of K_v1.1 to neuronal firing, we constructed a neuronal model containing a

repertoire of voltage-dependent ion channels (Fig. 5A) [43, 61–63]. The conductance densities were adjusted to generate an AP at a threshold of – 20 mV above RMP, and firing was elicited at suprathreshold currents.

K_v1.1 density was set at half of normal to mimic the reduction of K_v1.1 activity caused by LGII^{W183R}. Our simulation showed that K_v1.1 reduction significantly widened the AP (Fig. 5B). We then applied a rheobase current, which was sufficient to evoke a single AP in a cell containing normal K_v1.1, to a cell containing half of the K_v1.1. We found that the rheobase current induced a single AP in the cell with normal K_v1.1, but induced doublet APs in the cell with insufficient K_v1.1 (Fig. 5C). These results confirm that the pattern of neuronal APs is dependent on K_v1.1.

Next, we investigated the dependence of firing on the density of K_v1.1. Two levels of current injections (200 pA




Fig.5 Computer model of CA1 neuronal firing pattern. **A** A schematic model of a CA1 pyramidal neuron. **B** APs evoked by rheobase in the cell model containing normal (0.02) or the half (0.01) of K_v1.1. **C** The same strength of stimulation induces a single AP with K_v1.1 (0.02), but doublet APs with insufficient K_v1.1 (0.01). **D** A reduction in K_v1.1 results in more firing when the cell receives a 200-pA current injection (400 ms) (gray bars, intervals between 1st and 2nd spikes). **E** Reduced K_v1.1 results in less firing when the cell receives a 700-pA current injection (400 ms). **F** The amplifications of 1st and 4th spikes induced by 200-pA current. Note the difference in the half-width between 1st and 4th spikes, or between normal and half K_v1.1 conditions. **G** The amplifications of 1st and 5th AHPs and fitting analysis (gray lines) of AHP currents with normal or half K_v1.1

and 700 pA) were applied to the cell model as the low and high intensities of current injection, respectively. With 400-ms duration, 200-pA current induced 4 APs with normal $K_v1.1$, but 6 APs with half $K_v1.1$ (Fig. 5D). Moreover, the ISI between first two spikes was reduced in the cell with half $K_v1.1$ (Fig. 5D). However, 700-pA stimulation led to 8 spikes with normal $K_v1.1$, but 6 spikes with reduced $K_v1.1$ (Fig. 5E). The bidirectional change in the number of spikes with low and high intensities of stimulation is consistent with our whole-cell recording results. We amplified the spikes induced by 200-pA stimulation, and found that $K_v1.1$ reduction increased the half-width of 1st and 4th spikes (Fig. 5F). Moreover, the half-width ratio of 4th/1st spikes appeared more significant with reduced $K_v1.1$ (Fig. 5F), also consistent with our whole-cell recordings.

The resurgence of AHP current appeared slower with half $K_v1.1$ (Fig. 5E), which may explain the altered firing pattern. To test this point, we analyzed AHPs in early and late spikes with normal or fewer $K_v1.1$ channels. The polynomial fitting showed that $K_v1.1$ reduction caused a different pattern of fast AHP between the 1st to and the 2nd spikes, that is, the AHP tended to depolarize with normal $K_v1.1$ (slope coefficient: 68), but tended to hyperpolarize with reduced $K_v1.1$ (slope coefficient: -214) (Fig. 5G). Interestingly, in the follow-up AHPs, the difference began to decrease, showing that the slope coefficient was 30 for normal $K_v1.1$ and -3 for fewer $K_v1.1$ channels (Fig. 5G). Therefore, these data suggest that $K_v1.1$ reduction permits different firing pattern by delaying the onset of AHP currents.

Restoring $K_v1.1$ alleviates seizure susceptibility in cKO::LGII^{W183R} mice

Having demonstrated that reduced activity of $K_v1.1$ by LGII^{W183R} expression is responsible for epileptogenesis, an interesting question was whether the seizures can be ameliorated and whether the lifespan can be prolonged by restoring $K_v1.1$. To do so, we injected AAV9-DIO-LGII^{W183R}-GFP with AAV9-DIO- $K_v1.1$ -mCherry or AAV9-DIO-mCherry bilaterally into the ventricles of Het or cKO mice at P0 (Fig. 6A). Using this approach, LGII^{W183R} and $K_v1.1$, as exogenous proteins, were simultaneously expressed in excitatory neurons from cKO or Het mice. Later, the mice expressing LGII^{W183R} and $K_v1.1$ -mCherry or mCherry were subjected to video monitoring of autonomous or PTZ-induced seizures and/or electrophysiological recordings (Fig. 6A). The expression of LGII^{W183R} and $K_v1.1$ was confirmed by the fluorescence of GFP and mCherry, respectively. Figure 6B shows that both LGII^{W183R}-GFP and $K_v1.1$ -mCherry signals were robustly present in the temporal cortex and the hippocampus of cKO mice. Meanwhile, the

fluorescent signals of GFP and mCherry also co-localized with CaMKII α -Cre expressing neurons (Fig. 6B). Counting the numbers of GFP+mCherry+ and CaMKII α + neurons showed no difference in the ratio of GFP+mCherry+ neurons among CaMKII α + neurons either between mCherry and $K_v1.1$ groups at two developmental stages (Fig. 6C). These results indicate that exogenous LGII^{W183R} and $K_v1.1$ are robustly expressed in excitatory neurons. Again, GFP and mCherry signals did not co-localize with the marker proteins for other major types of nerve cells (Additional file 3: Fig. S3).

The majority of cKO::LGII^{W183R}::mCherry mice (15/18) died before P21 with a median lifetime of 22 days (Fig. 6D). In contrast, the majority of cKO::LGII^{W183R}:: $K_v1.1$ littermates survived beyond this period with a median lifetime of 29 days (Fig. 6D). Video monitoring showed that cKO::LGII^{W183R}:: $K_v1.1$ mice exhibited a significant reduction in seizures (Additional file 10: Movie S2 and Additional file 5: Table S2). Furthermore, we examined PTZ-induced seizures in Het::LGII^{W183R}:: $K_v1.1$ and Het::LGII^{W183R}::mCherry mice, and found that seizure severity was significantly less in Het::LGII^{W183R}:: $K_v1.1$ mice: most (10/15) Het::LGII^{W183R}::mCherry mice were at stages 3/4, whereas most Het::LGII^{W183R}:: $K_v1.1$ mice (10/15) were at stages 1/2 and had an increased latency to generalized seizures (Fig. 6E). Energy spectra of epileptic EEGs recorded from Het::LGII^{W183R}::mCherry and Het::LGII^{W183R}:: $K_v1.1$ mice are shown in Fig. 6F and the absolute power for at each firing frequency is shown in Fig. 6G. Our results indicated that restoring $K_v1.1$ significantly reduced PTZ-induced seizure severity in Het::LGII^{W183R} mice. In summary, we conclude that restoring $K_v1.1$ alleviates seizure susceptibility and extends the lifespan of cKO::LGII^{W183R} mice.

Restoration of cKO::LGII^{W183R} neuronal excitability by expressing $K_v1.1$

If restoring $K_v1.1$ reduces epileptic seizures, it should be able to reverse the impaired intrinsic excitability in neurons expressing LGII^{W183R}. To address this point, we expressed $K_v1.1$ in excitatory neurons of cKO::LGII^{W183R} mice and made whole-cell recordings from these neurons. We found that expressing $K_v1.1$, but not control mCherry, effectively restored $K_v1.1$ current in cKO::LGII^{W183R} neurons (Fig. 7A). Kinetics analysis showed that expressing $K_v1.1$ rescued the defective activation and inactivation of $K_v1.1$ currents, showing a decreased half-inactivation voltage in cKO::LGII^{W183R} neurons expressing $K_v1.1$ (Fig. 7B).

We continued to study the effects of $K_v1.1$ expression on the AP, firing frequency and regularity. First, expressing $K_v1.1$ made the AP waveform of cKO::LGII^{W183R}




Fig.6 Reduced seizure susceptibility after Kv1.1 restoring. **A** AAV9-DIO-Kv1.1-mCherry or AAV9-DIO-mCherry accompanied by AAV9-DIO-LGI1^{W183R}-GFP expressed in excitatory neurons. The viruses were injected bilaterally into the ventricles of cKO or Het mice at P0. **B** Representative images for quadruple-fluorescence (GFP, mCherry, CaMKII and DAPI) in the hippocampus (hip) and temporal cortex (temp lb) of cKO mice (P17). Scale bars: 1 mm (whole brain) and 50 μm (magnified). **C** The ratios of numbers of GFP + mCherry + vs CaMKII + cells ($n = 5$ mice per group) at P17-20 were 41 ± 3 (CA1; cKO::LGI1^{W183R}::mCherry) and 44 ± 4 (CA1; cKO::LGI1^{W183R}::Kv1.1), $P = 0.64$; 42 ± 3 (temp lb; cKO::LGI1^{W183R}::mCherry) and 41 ± 7 (temp lb; cKO::LGI1^{W183R}::Kv1.1), $P = 0.88$. At P35, the ratio were 41 ± 3 (CA1; cKO::LGI1^{W183R}::mCherry) and 40 ± 5 (CA1; cKO::LGI1^{W183R}::Kv1.1), $P = 0.92$; 40 ± 4 (temp lb; cKO::LGI1^{W183R}::mCherry) and 42 ± 2 (temp lb; cKO::LGI1^{W183R}::Kv1.1), $P = 0.72$. **D** Kaplan–Meier curves. **E** Reactions to PTZ injection of Het::LGI1^{W183R}::mCherry and Het::LGI1^{W183R}::Kv1.1 mice. Latency to generalized seizure (GS): 228 ± 31 s (Het::LGI1^{W183R}::mCherry; $n = 10$) and 409 ± 59 s (Het::LGI1^{W183R}::Kv1.1; $n = 5$), $P = 0.033$. **F** Example EEG recordings in cKO::LGI1^{W183R}::mCherry and cKO::LGI1^{W183R}::Kv1.1 mice (P35) during PTZ-induced seizures. **F'** Enlarged view of EEGs in **F**. **G** Spectral analysis of EEGs. * $P < 0.05$

neurons similar to cKO::LGI1^{WT} neurons, and significantly restored the threshold, rheobase, and half-width that were changed by LGI1^{W183R} (Fig. 7C). Second, cKO::LGI1^{W183R}::Kv1.1 neurons had fewer

spikes in response to current injection (Fig. 7D). Third, the half-width of spikes was significantly reduced in cKO::LGI1^{W183R}::Kv1.1 neurons in response to stepped current injections (Fig. 7E). Moreover, the half-width




Fig. 7 Restoring $K_v1.1$ rescues neuronal excitability. **A** Left: example $K_v1.1$ current activated by stepped pulses in cKO::LGI1^{W183R}::mCherry and cKO::LGI1^{W183R}::Kv1.1 pyramidal neurons. Right: plots of current–voltage relationship of $K_v1.1$ current. **B** Averages of activation half-voltage, slope of activation curve, inactivation half-voltage, and slope of the inactivation curve. **C** Left: example APs and phase-plane plots. Right: averages of threshold, rheobase, and half-width of APs. **D** Left: example spikes of cKO::LGI1^{W183R}::mCherry and cKO::LGI1^{W183R}::Kv1.1 neurons. Right: input–output curves showing numbers of spikes as a function of injected current. **E** Left: example 1st and last spikes induced by a 200-pA current in cKO::LGI1^{W183R}::mCherry and cKO::LGI1^{W183R}::Kv1.1 neurons. Middle: half-width of 1st spike induced by different currents plotted against current. Right: ratios of the last vs 1st spike plotted against inject current. **F** Left: example firing showing spike-timing reliability. Right: plots of intraburst jitter as a function of recording time. **G** Averages of 1st ISI frequency, CV, and CV₂. **H** Plots of fast AHP as a function of spikes. See Additional file 7: Table S5 for statistics. Grey dots indicate individual data points. * $P < 0.05$. ** $P < 0.01$. *** $P < 0.001$

ratio of last vs 1st spikes was also significantly reduced by $K_v1.1$ expression for the high intensity currents (Fig. 7E), which explains the increased number of spikes under these conditions (Fig. 7D). Fourth, the spiking irregularity of cKO::LGI1^{W183R} was rescued by the expression of $K_v1.1$. As shown by 7 spikes and activity raster (Fig. 7F), $K_v1.1$ expression relaxed the firing pattern of cKO::LGI1^{W183R} neurons, making it close to that of WT neurons. The statistics indicated that 1st ISI, CV, and CV₂ all decreased in cKO::LGI1^{W183R}:: $K_v1.1$ neurons in comparison with cKO::LGI1^{W183R}::mCherry neurons (Fig. 7G). Finally, we measured the fast AHPs of spikes in cKO::LGI1^{W183R}::mCherry and cKO::LGI1^{W183R}:: $K_v1.1$ neurons, and found that $K_v1.1$ rescued the deficit of the fast AHP in cKO::LGI1^{W183R} neurons (Fig. 7H). This result explains the return of spiking regularity in cKO::LGI1^{W183R}:: $K_v1.1$ neurons. Taken together, restoring $K_v1.1$ rescues the impaired AP kinetics and firing pattern in cKO::LGI1^{W183R} neurons.

Discussion

Endogenous LGI1 has two homologous isomers: the shorter is secreted, while the longer is not secreted and is retained inside cells [11], suggesting that LGI1 may affect neuronal activity through different mechanisms. Secreted LGI1 acts as a ligand to bind to ADAM22 at postsynaptic sites of excitatory synapses and regulates synaptic development and AMPA receptor-mediated neurotransmission [24]. If LGI1 is knocked out globally, synaptic transmission is disrupted and neuronal excitability is altered, resulting in autonomous epilepsy and pre-mature death in mice [28, 64]. In contrast, no epileptic symptoms are observed when LGI1 is knocked out in either interneurons or astrocytes [19]. These findings demonstrate the crucial roles of LGI1 secreted from excitatory neurons in epileptogenesis.

These results may lead to a mystery: why can't the LGI1 secreted from other types of nerve cell compensate for the loss of LGI1 from excitatory neurons? As a matter of fact, it has been shown that LGI1 is expressed in PV-positive interneurons, astrocytes and oligodendrocytes [19, 20]. In addition, LGI1 can act on adjacent synapses through both paracrine and autocrine mechanisms [25]. These results imply that the LGI1 from interneurons and astrocytes would act on excitatory synapses, which may make the LGI1 from excitatory neurons appear dispensable. Our previous work solved this paradox, showing that LGI1 deficiency can disable K_v1 channels in excitatory neurons, thereby increasing neuronal firing [18]. Thus, functional LGI1 inside neurons may also be critical for maintaining normal neuronal function.

Compared to mouse models with LGI1 deficiency, the situation of dysfunctional LGI1 is more complicated in

ADLTE patients. Among 41 LGI1 missense mutations found in familial ADLTE patients, more than half are secretion-defective with different secretion probabilities [3–12, 26, 28]. While the ADLTE patients with secretion-defective LGI1 mutations display epileptic seizures as well, the role of secretion-defective LGI1 on neuronal activity has been unclear. Yokoi et al. [28], examined a mouse model of familial epilepsy with the secretion-defective LGI1 mutation, LGI1^{E383A}, and their findings suggested that this mutation may damage the structure of LGI1 protein and cause its rapid degradation, resulting in a condition similar to the deletion of LGI1. Moreover, they demonstrated that an improvement of LGI1 secretion by 4PBA, a chemical corrector, reduces the risk of developing epilepsy in mouse with LGI1 secretion-defective mutations [28]. However, there is a lack of evidence for the assertion that secretion-defective LGI1 mutations lead to the degradation of LGI1 protein. In fact, the LGI1^{E383A} mutation occurs at the EPTP domain of LGI1 [26, 28], which may only affect the binding between LGI1 and ADAM22 [26]. Thus, it is unclear whether and what role the secretion-defective LGI1 proteins play in the cytosol.

Here, we showed that with LGI1^{W183R}, a novel secretion-defective mutation, LGI1 protein is robustly expressed and its ubiquitination level is not changed by the mutation. Therefore, the secretion-defective mutations of LGI1 may affect neuronal activity through an alternative mechanism, not only degradation. It has been shown that LGI1 co-localizes with K_v1 at the axonal initial segment [22] and LGI1 regulates the inactivation of $K_v1.1$ channel [21]. These studies suggest that LGI1 protein in the cytosol is critical to the stability and regulates the activity of K_v1 channels. Indeed, we here provide evidence showing that LGI1^{W183R} mutation negatively regulates $K_v1.1$ activity and leads to neuronal hyperactivity, resulting in epileptic seizures. Therefore, our findings answer how neuronal hyperactivity is induced by a secretion-defective LGI1 mutation and this intrinsic disorder is not saved by paracrine LGI1. Based on existing studies, we speculate that LGI1 acts on neuronal activity by regulating the function of excitatory synapses and the activity of K_v1 channels. Recently, Baudin et al. [23] found that inhibiting $K_v1.1$ alters neuronal excitability, mimicking anti-LGI1-associated seizures and supporting our findings. We found that dysfunctional $K_v1.1$ increases neuronal firing irregularity, consistent with the results reported in cortical neurons [49]. Furthermore, the irregular discharges of hippocampal neurons concur with the emergence of seizure in epileptic rats [65]. Based on these studies, we conclude that irregular spikes caused by $K_v1.1$ dysregulation are partly responsible for the epilepsy in LGI1^{W183R} mice. Yet, LGI1 may have other functional

partners, which may explain why restoring $K_v1.1$ does not fully rescue the life span of $LGII^{W183R}$ mice. In addition to the molecular partners of $LGII$ in excitatory neurons, we cannot neglect the potential roles of $LGII$ in inhibitory neurons and non-neuronal complexes, such as astrocytes and oligodendrocytes, since $LGII$ also occurs in inhibitory synaptic sites as well as neuronal-glia protein complex [20]. Another intriguing question is that $LGII$ may play roles in glioma genesis and oligodendrocyte differentiation and myelination [14, 66].

$LGII$ mutations are distributed in all domains of $LGII$, implying the distinct actions of these mutations. During the treatment of ADLTE patients carrying a certain $LGII$ missense mutation, it is necessary to clarify the specific function of the mutation and determine its major action. After all, >40 $LGII$ mutations must be linked to distinct secretion probabilities and regulatory actions. In this way, it is essential for precision medicine to conduct large-scale functional analysis of human familial ADLTE-linked mutations. At present, other three mutations, c.535t>c, c.598t>c, and c.641t>c, have been found in the C-cap domain as well. It is known that these mutations are also secretion-defective [26, 28], but unknown whether they affect K_v1 channel activity. In fact, the binding affinity to partner molecules has been studied for almost all no mutations, except for the binding between a few mutations of $LGII$ and ADAM22 [26]. Therefore, it is necessary to clarify the impact of $LGII$ mutations on the structure and binding ability to its partner molecules in the future.

Conclusions

In sum, we found a novel pathogenic variant of $LGII$ in a Chinese family suffering ADLTE, expanding the spectrum of causative variants of $LGII$. We unveiled the pathogenic mechanism exhibited by the p.Trp183Arg missense mutation in epileptic seizures, showing that this mutation produced secretion-defective $LGII^{W183R}$ protein, which caused the hyperexcitability and firing irregularity of excitatory neurons, and epileptic seizures in mice by downregulating $K_v1.1$ activity. Moreover, restoring $K_v1.1$ in excitatory neurons was able to correct the deficits in firing and ameliorate seizure susceptibility. Therefore, our work reveals a new mechanism by which a secretion-defective $LGII$ protein causes neuronal dysfunction and familial epilepsy.

Abbreviations

ADAMs	A disintegrin and metalloproteinases
ADLTE	Autosomal dominant lateral temporal epilepsy
AHP	After-hyperpolarization potential
AP	Action potential

CHX	Cycloheximide
C_m	Membrane capacitance
C_v	Coefficient of variation
EEG	Electroencephalogram
GS	Generalized seizure
ISI	Interspike interval
$LGII$	Leucine-rich glioma inactivated 1
MRI	Magnetic resonance imaging
PTZ	Pentylenetetrazole
PV	Parvalbumin
RMP	Resting membrane potential

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13578-023-00983-y>.

Additional file 1. Figure S1. Expressing $LGII^{W183R}$ in excitatory neurons does not affect other types of nerve cells. AAV9-DIO- $LGII^{W183R}$ -GFP was injected bilaterally into the ventricles of cKO mice (P0). Representative images for triple fluorescence of GFP, individual marker proteins (PV, GFAP, Iba1, and NeuN), and DAPI, show that $LGII^{W183R}$ is not expressed in PV-positive interneurons, astroglia (GFAP) and microglia (Iba1) in the hippocampus and temporal cortex of cKO mice (P17). Scale bars: 1 mm (whole brain) and 50 μ m (magnified).

Additional file 2. Figure S2. Unchanged excitatory transmission in $LGII^{W183R}$ neurons. (A) Example mEPSCs from cKO: $LGII^{WT}$ and cKO: $LGII^{W183R}$ mice (P17). (B) Cumulative plots of mEPSC amplitude. (C) Mean values of mEPSC frequency: 0.23 ± 0.02 Hz (cKO: $LGII^{WT}$; n = 7) and 0.22 ± 0.03 Hz (cKO: $LGII^{W183R}$; n = 9), P = 0.88.

Additional file 3. Figure S3. Restoring $K_v1.1$ in excitatory neurons does not affect other types of nerve cells. AAV9-DIO- $LGII^{W183R}$ -GFP and AAV9-DIO- $K_v1.1$ -mCherry were bilaterally injected into the ventricles of cKO mice (P0). Representative images for quadruple fluorescence of GFP, mCherry, individual marker proteins (PV, GFAP, Iba1, and NeuN), and DAPI, show that $LGII^{W183R}$ is not expressed in PV-positive interneurons, astroglia (GFAP) and microglia (Iba1) in the hippocampus and temporal cortex of cKO mice (P17). Scale bars: 1 mm (whole brain) and 50 μ m (magnified).

Additional file 4. Table S1. The statistics for Fig. 1G, 1H, 1J, and 1K.

Additional file 5. Table S2. The statistics of spontaneous seizures.

Additional file 6. Table S3. The statistics for Fig. 3C, 3G, 3H, 3J and 3K.

Additional file 7. Table S4. The statistics for Fig. 4C, 4D, 4H, 4I, 4J and 4L.

Additional file 8. Table S5. The statistics for Fig. 7A, 7B, 7C, 7D, 7E, 7G and 7H.

Additional file 9. Movie 1. A cKO: $LGII^{WT}$ mouse (P20; right) behaves normally, while another cKO: $LGII^{W183R}$ mouse (P20; left) displays epileptic seizures. MPEG-4 format, 4.8 MB.

Additional file 10. Movie 2. A cKO: $LGII^{W183R}$:mCherry mouse (P20; right) displays epileptic seizures, while another cKO: $LGII^{W183R}$: $K_v1.1$ mouse (P20; left) behaves normally. MPEG-4 format, 6.2 MB

Additional file 11. Proband clinical information.

Additional file 12. Proband family sequencing result.

Acknowledgements

We thank Drs. Yan Gu, Jia-Dong Chen, Yu-Guo Yu, Lu-Xi Wang, and other lab members for their critical comments; and the core facility of Zhejiang University Institute of Neuroscience for technical assistance.

Author contributions

LZ, KW, WC, YS and JSW designed the research; LZ, KW, XYX, BBD, DCW, ZXW, XTW, JTY, and RZ performed the research; LZ, KW, XYX, BBD, DCW, ZXW, and XTW analyzed data; DCW, ZXW, ZYW, and JSW supplied reagents/analytic tools; LZ, KW, WC, YS and JSW wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the Ministry of Science and Technology of China (2020YFB1313500 to LZ); the National Natural Science Foundation of China (81625006 to YS, 31820103005 to YS, 31900741 to LZ, 32170976 to LZ, 81271410 to JSW, and 32161143021 to JSW); the Zhejiang Province Natural Science Foundation of China (LY21C090003 to LZ, LY19H090020 to DCW); the Science and Technology Programme of Hangzhou Municipality (20190101A10 to WC); the Key Realm R&D Program of Guangdong Province (2019B030335001 to WC); the Henan Province Natural Science Foundation of China (182300410313 to JSW); and Bio-Med Interdisciplinary Innovative Program of Henan University (CJ1205A0240018 to JSW).

Availability of data and materials

Any additional data and materials are available from corresponding authors on reasonable request.

Declarations

Ethics approval and consent to participate

The human study in the present work was approved by the Ethics Committee of First Affiliated Hospital of Zhejiang University School of Medicine (#2017–326). The patient and his family signed written informed consents prior to participation. The animal experiments were approved by the Animal Experimentation Ethics Committee of Zhejiang University.

Consent for publication

All the listed authors have participated in the study, and have seen and approved the submitted manuscript.

Competing interests

The authors have declared that no conflict of interest exists.

Received: 30 December 2022 Accepted: 4 February 2023

Published online: 20 February 2023

References

- Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. *Epilepsia*. 2010;51:883–90.
- Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. *JAMA Neurol*. 2018;75:279–86.
- Gu W, Brodtkorb E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. *Ann Neurol*. 2002;52:364–7.
- Kalachikov S, Evgrafov O, Ross B, Winawer M, Barker-Cummings C, Martinelli Boneschi F, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. *Nat Genet*. 2002;30:335–41.
- Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, Saenz A, Poza JJ, Galan J, et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. *Hum Mol Genet*. 2002;11:1119–28.
- Fertig E, Lincoln A, Martinuzzi A, Mattson RH, Hisama FM. Novel LGI1 mutation in a family with autosomal dominant partial epilepsy with auditory features. *Neurology*. 2003;60:1687–90.
- Berkovic SF, Izzillo P, McMahon JM, Harkin LA, McIntosh AM, Phillips HA, et al. LGI1 mutations in temporal lobe epilepsies. *Neurology*. 2004;62:1115–9.
- Bisulli F, Tinuper P, Scudellaro E, Naldi I, Bagattin A, Avoni P, et al. A de novo LGI1 mutation in sporadic partial epilepsy with auditory features. *Annals Neurol*. 2004;56:455–6.
- Ottman R, Winawer MR, Kalachikov S, Barker-Cummings C, Gilliam TC, Pedley TA, et al. LGI1 mutations in autosomal dominant partial epilepsy with auditory features. *Neurology*. 2004;62:1120–6.
- Sirerol-Piquer MS, Ayerdi-Izquierdo A, Morante-Redolat JM, Herranz-Perez V, Favell K, Barker PA, et al. The epilepsy gene LGI1 encodes a secreted glycoprotein that binds to the cell surface. *Hum Mol Genet*. 2006;15:3436–45.
- Furlan S, Roncaroli F, Forner F, Vitiello L, Calabria E, Piquer-Sirerol S, et al. The LGI1/epitempin gene encodes two protein isoforms differentially expressed in human brain. *J Neurochem*. 2006;98:985–91.
- Dazzo E, Leonardi E, Belluzzi E, Malacrida S, Vitiello L, Greggio E, et al. Secretion-positive LGI1 mutations linked to lateral temporal epilepsy impair binding to ADAM22 and ADAM23 receptors. *PLoS Genet*. 2016;12:e1006376.
- Pizzuti A, Flex E, Di Bonaventura C, Dottorini T, Egeo G, Manfredi M, et al. Epilepsy with auditory features: a LGI1 gene mutation suggests a loss-of-function mechanism. *Ann Neurol*. 2003;53:396–9.
- Senchal KR, Thaller C, Noebels JL. ADPEAF mutations reduce levels of secreted LGI1, a putative tumor suppressor protein linked to epilepsy. *Hum Mol Genet*. 2005;14:1613–20.
- Chabrol E, Navarro V, Provenzano G, Cohen I, Dinocourt C, Rivaud-Pechoux S, et al. Electroclinical characterization of epileptic seizures in leucine-rich, glioma-inactivated 1-deficient mice. *Brain*. 2010;133:2749–62.
- Fukata Y, Lovero KL, Iwanaga T, Watanabe A, Yokoi N, Tabuchi K, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. *Proc Natl Acad Sci USA*. 2010;107:3799–804.
- Yu YE, Wen L, Silva J, Li Z, Head K, Sossey-Alaoui K, et al. Lgi1 null mutant mice exhibit myoclonic seizures and CA1 neuronal hyperexcitability. *Hum Mol Genet*. 2010;19:1702–11.
- Zhou L, Zhou L, Su LD, Cao SL, Xie YJ, Wang N, et al. Celecoxib ameliorates seizure susceptibility in autosomal dominant lateral temporal epilepsy. *J Neurosci*. 2018;38:3346–57.
- Boillot M, Huneau C, Marsan E, Lehongre K, Navarro V, Ishida S, et al. Glutamatergic neuron-targeted loss of LGI1 epilepsy gene results in seizures. *Brain*. 2014;137:2984–96.
- Ramirez-Franco J, Debreux K, Extremet J, Maulet Y, Belghazi M, Villard C, et al. Patient-derived antibodies reveal the subcellular distribution and heterogeneous interactome of LGI1. *Brain*. 2022;145:3843–58.
- Schulte U, Thumfart JO, Klocker N, Sailer CA, Bildl W, Biniossek M, et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. *Neuron*. 2006;49:697–706.
- Seagar M, Russier M, Caillard O, Maulet Y, Fronzaroli-Molinieres L, De San FM, et al. LGI1 tunes intrinsic excitability by regulating the density of axonal Kv1 channels. *Proc Natl Acad Sci USA*. 2017;114:7719–24.
- Baudin P, Whitmarsh S, Cousyn L, Roussel D, Lecas S, Lehongre K, et al. Kv1.1 channels inhibition in the rat motor cortex recapitulates seizures associated with anti-LGI1 encephalitis. *Prog Neurobiol*. 2022;213:102262.
- Fukata Y, Adesnik H, Iwanaga T, Bredt DS, Nicoll RA, Fukata M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. *Science*. 2006;313:1792–5.
- Lovero KL, Fukata Y, Granger AJ, Fukata M, Nicoll RA. The LGI1-ADAM22 protein complex directs synapse maturation through regulation of PSD-95 function. *Proc Natl Acad Sci USA*. 2015;112:E4129–37.
- Yamagata A, Miyazaki Y, Yokoi N, Shigematsu H, Sato Y, Goto-Ito S, et al. Structural basis of epilepsy-related ligand-receptor complex LGI1-ADAM22. *Nat Commun*. 2018;9:1546.
- Fukata Y, Chen X, Chiken S, Hirano Y, Yamagata A, Inahashi H, et al. LGI1-ADAM22-MAGUK configures transsynaptic nanoalignment for synaptic transmission and epilepsy prevention. *Proc Natl Acad Sci USA*. 2021;118:e2022580118.
- Yokoi N, Fukata Y, Kase D, Miyazaki T, Jaegle M, Ohkawa T, et al. Chemical corrector treatment ameliorates increased seizure susceptibility in a mouse model of familial epilepsy. *Nat Med*. 2015;21:19–26.
- van der Knoop MM, Maroofian R, Fukata Y, van Ierland Y, Karimiani EG, Lehesjoki AE, et al. Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy. *Brain*. 2022;145:2301–12.
- Chen W, Luo B, Gao N, Li H, Wang H, Li L, et al. Neddylation stabilizes Nav1.1 to maintain interneuron excitability and prevent seizures in murine epilepsy models. *J Clin Invest*. 2021;131:e136956.
- Kim JY, Ash RT, Ceballos-Diaz C, Levites Y, Golde TE, Smirnakis SM, et al. Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo. *Eur J Neurosci*. 2013;37:1203–20.
- Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. 3rd ed. San Diego: Academic Press; 2007.

33. Wu D, Fei F, Zhang Q, Wang X, Gong Y, Chen X, et al. Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy. *Sci Adv*. 2022;8:3381.
34. Fourcaud-Trocme N, Zbili M, Duchamp-Viret P, Kuczewski N. Afterhyperpolarization promotes the firing of mitral cells through a voltage-dependent modification of action potential threshold. *eNeuro*. 2022. <https://doi.org/10.1523/ENEURO.0401-21.2021>.
35. Dumenieu M, Fourcaud-Trocme N, Garcia S, Kuczewski N. Afterhyperpolarization (AHP) regulates the frequency and timing of action potentials in the mitral cells of the olfactory bulb: role of olfactory experience. *Physiol Rep*. 2015;3: e12344.
36. Liu X, Qiao Z, Chai Y, Zhu Z, Wu K, Ji W, et al. Nonthermal and reversible control of neuronal signaling and behavior by midinfrared stimulation. *Proc Natl Acad Sci USA*. 2021;118: e2015685118.
37. Sigworth FJ. The variance of sodium current fluctuations at the node of Ranvier. *J Physiol*. 1980;307:97–129.
38. Li J, Correa AM. Kinetic modulation of HERG potassium channels by the volatile anesthetic halothane. *Anesthesiology*. 2002;97:921–30.
39. Hartveit E, Veruki ML. Studying properties of neurotransmitter receptors by non-stationary noise analysis of spontaneous synaptic currents. *J Physiol*. 2006;574:751–85.
40. Hartveit E, Veruki ML. Studying properties of neurotransmitter receptors by non-stationary noise analysis of spontaneous postsynaptic currents and agonist-evoked responses in outside-out patches. *Nat Protoc*. 2007;2:434–48.
41. Traynelis SF, Silver RA, Cull-Candy SG. Estimated conductance of glutamate receptor channels activated during EPSCs at the cerebellar mossy fiber-granule cell synapse. *Neuron*. 1993;11:279–89.
42. Steffan R, Heinemann SH. Error estimates for results of nonstationary noise analysis derived with linear least squares methods. *J Neurosci Methods*. 1997;78:51–63.
43. Shah MM, Migliore M, Valencia I, Cooper EC, Brown DA. Functional significance of axonal Kv7 channels in hippocampal pyramidal neurons. *Proc Natl Acad Sci USA*. 2008;105:7869–74.
44. Hines ML, Carnevale NT. The NEURON simulation environment. *Neural Comput*. 1997;9:1179–209.
45. Migliore M, Shepherd GM. Emerging rules for the distributions of active dendritic conductances. *Nat Rev Neurosci*. 2002;3:362–70.
46. Kole MH, Ilschner SU, Kampa BM, Williams SR, Ruben PC, Stuart GJ. Action potential generation requires a high sodium channel density in the axon initial segment. *Nat Neurosci*. 2008;11:178–86.
47. Zerr P, Adelman JP, Maylie J. Episodic ataxia mutations in Kv1.1 alter potassium channel function by dominant negative effects or haploinsufficiency. *J Neurosci*. 1998;18:2842–8.
48. Winawer MR, Ottman R, Hauser WA, Pedley TA. Autosomal dominant partial epilepsy with auditory features: defining the phenotype. *Neurology*. 2000;54:2173–6.
49. Rodriguez-Tornos FM, Briz CG, Weiss LA, Sebastian-Serrano A, Ares S, Navarrete M, et al. Cux1 enables interhemispheric connections of layer II/III neurons by regulating Kv1-dependent firing. *Neuron*. 2016;89:494–506.
50. Xu FX, Zhou L, Wang XT, Jia F, Ma KY, Wang N, et al. Magneto is ineffective in controlling electrical properties of cerebellar Purkinje cells. *Nat Neurosci*. 2020;23:1041–3.
51. Sah P, Faber ES. Channels underlying neuronal calcium-activated potassium currents. *Prog Neurobiol*. 2002;66:345–53.
52. Matthews EA, Linardakis JM, Disterhoft JF. The fast and slow afterhyperpolarizations are differentially modulated in hippocampal neurons by aging and learning. *J Neurosci*. 2009;29:4750–5.
53. Schweitz H, Bidard JN, Lazdunski M. Purification and pharmacological characterization of peptide toxins from the black mamba (*Dendroaspis polylepis*) venom. *Toxicon*. 1990;28:847–56.
54. Wang FC, Bell N, Reid P, Smith LA, McIntosh P, Robertson B, et al. Identification of residues in dendrotoxin K responsible for its discrimination between neuronal K⁺ channels containing Kv1.1 and 1.2 alpha subunits. *Eur J Biochem*. 1999;263:222–9.
55. Xiao Y, Yang J, Ji W, He Q, Mao L, Shu Y. A- and D-type potassium currents regulate axonal action potential repolarization in midbrain dopamine neurons. *Neuropharmacol*. 2021;185: 108399.
56. Zheng Y, Liu P, Bai L, Trimmer JS, Bean BP, Ginty DD. Deep sequencing of somatosensory neurons reveals molecular determinants of intrinsic physiological properties. *Neuron*. 2019;103:598–616.
57. Yang J, Ye M, Tian C, Yang M, Wang Y, Shu Y. Dopaminergic modulation of axonal potassium channels and action potential waveform in pyramidal neurons of prefrontal cortex. *J Physiol*. 2013;591:3233–51.
58. Guan D, Lee JC, Higgs MH, Spain WJ, Foehring RC. Functional roles of Kv1 channels in neocortical pyramidal neurons. *J Neurophysiol*. 2007;97:1931–40.
59. Alvarez O, Gonzalez C, Latorre R. Counting channels: a tutorial guide on ion channel fluctuation analysis. *Adv Physiol Educ*. 2002;26:327–41.
60. Zakany F, Pap P, Papp F, Kovacs T, Nagy P, Peter M, et al. Determining the target of membrane sterols on voltage-gated potassium channels. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2019;1864:312–25.
61. Goldberg EM, Clark BD, Zagha E, Nahmani M, Erisir A, Rudy B. K⁺ channels at the axon initial segment dampen near-threshold excitability of neocortical fast-spiking GABAergic interneurons. *Neuron*. 2008;58:387–400.
62. Hemond P, Epstein D, Boley A, Migliore M, Ascoli GA, Jaffe DB. Distinct classes of pyramidal cells exhibit mutually exclusive firing patterns in hippocampal area CA3b. *Hippocampus*. 2008;18:411–24.
63. Henze DA, Cameron WE, Barrionuevo G. Dendritic morphology and its effects on the amplitude and rise-time of synaptic signals in hippocampal CA3 pyramidal cells. *J Comp Neurol*. 1996;369:331–44.
64. Yokoi N, Fukata Y, Okatsu K, Yamagata A, Liu Y, Sanbo M, et al. 14-3-3 proteins stabilize LGI1-ADAM22 levels to regulate seizure thresholds in mice. *Cell Rep*. 2021;37: 110107.
65. Foffani G, Uzcategui YG, Gal B, Menendez de la Prida L. Reduced spike-timing reliability correlates with the emergence of fast ripples in the rat epileptic hippocampus. *Neuron*. 2007;55:930–41.
66. Xie YJ, Zhou L, Wang Y, Jiang NW, Cao S, Shao CY, et al. Leucine-rich glioma inactivated 1 promotes oligodendrocyte differentiation and myelination via TSC-mTOR signaling. *Front Mol Neurosci*. 2018;11:231.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

